Search Results
Feb 24, 2026, 19:30 ET Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)
for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune disease, solid tumors and hematological malignancies
More news about: Antengene Corporation Limited
Feb 19, 2026, 06:49 ET Tata Consumer Products Collaborates with CSIR-NIIST to Advance Science-Backed Food and Beverage Innovations
households, giving it an unparalleled ability to leverage the Tata brand in consumer products. The Company has a consolidated annual turnover of Rs. 17,618 Crs with operations in India and International markets.For more information on the Company, please visit our website
More news about: Tata Consumer Products Limited
Feb 17, 2026, 10:00 ET Alaska Airlines Becomes First Carrier to Fully Integrate Digital Payment System with PayCargo and IBS Software
management. Across the hospitality sector, IBS Software offers a cloud-native, unified platform for hotels and travel sellers, including central reservation (CRS), property management (PMS), revenue management (RMS), call centre, booking engine, loyalty, and distribution. For the tour & cruise industry, IBS
More news about: PayCargo
Feb 17, 2026, 08:27 ET RMX Positions VAST™ as Critical Data Backbone for Next-Generation Counter-UAS Networks
https://www.congress.gov/crs-product/IN12418
More news about: RMX Industries, Inc.
Feb 10, 2026, 06:59 ET Carbon Credit Validation, Verification, and Certification Market worth $448.0 million in 2030 | MarketsandMarkets™
(Luxembourg), Aster Global Environmental Solutions, Inc. (US), Carbon Check (India), Ancer Climate, LLC (US), Carbon trust (UK), First Environment Inc. (US), CRS (US), Cotecna (Switzerland), and Carbon credit Capital (US).Request Sample Pages:
More news about: MarketsandMarkets
Feb 02, 2026, 18:53 ET Inspired Healthcare Capital Initiates Strategic Restructuring to Explore Options to Maximize Stakeholder Value
Company significantly changed its corporate governance and leadership structure, replacing the former senior leadership team with independent managers. CRS Capstone Partners, LLC was appointed independent manager and director of IHC and IHC Holdings, and Trinity River Associates, LLC now serves as independent
More news about: Inspired Healthcare Capital
Feb 02, 2026, 09:12 ET Aarti Industries Delivers Robust Sequential Growth in Q3 FY26 Amid Global Volatility; Advances Portfolio Integration and Balanced Growth Strategy
crore, marking a 11% Q-o-Q increase. The company has provided for a one time impact on account of implementation of the new labour code of about Rs 15 crs as an exceptional expenses for the period. The company awaits the state and central government notification to refine its working and hence will take
More news about: Aarti Industries
Feb 01, 2026, 23:00 ET Gstar's Solar Module Series First to Achieve India's New BIS Certification
In India, BIS certification is mandatory for all PV modules under the Compulsory Registration Scheme (CRS). Only BIS-certified modules are eligible for legal import, sale, and deployment in India, including government and public-sector projects. Achieving
More news about: Gstar Solar
Feb 01, 2026, 23:00 ET Gstar की सोलर मॉड्यूल सिरीज़, भारत का नया BIS प्रमाणन प्राप्त करने वाली पहली मॉड्यूल बनी
भारत में, Compulsory Registration Scheme (CRS) के तहत सभी PV मॉड्यूलों के लिए BIS प्रमाणन अनिवार्य है। भारत में सरकारी और सार्वजनिक क्षेत्र की परियोजनाओं सहित, केवल BIS-प्रमाणित मॉड्यूल ही कानूनी
More news about: Gstar Solar
Jan 31, 2026, 07:57 ET Piramal Pharma Limited annuncia i risultati del terzo trimestre e dei primi nove mesi dell'anno fiscale 2026
Include indennità di fine rapporto e liquidazione delle ferie a causa dell'impatto della modifica alla legge LWF ₹ 26 Crs. e accordo con i clienti CDMO ₹ 15 Crs. 9MFY26 – Include voci eccezionali del terzo trimestre dell'anno fiscale 2026 parzialmente compensate da proventi una
More news about: Piramal Pharma Limited
Jan 31, 2026, 03:15 ET Sanyou Bio's Decade: From an Intelligent Super-Trillion Antibody Library to the "Innovation Hub for Original Drug Discovery"
dramatically reducing the complexity and cost of managing multiple vendors.At the same time, tools such as the OneClick+ Online Design Platform and the CRS marketplace, transform deep expert knowledge into standardized, user-friendly products and services, significantly shortening project initiation cycles.According
More news about: Sanyou Bio
Jan 30, 2026, 03:07 ET Piramal Pharma Limited gibt Ergebnisse für das dritte Quartal und die ersten neun Monate des Geschäftsjahres 2026 bekannt
LWF-Gesetzes ₹ 26 Crs. & Vergleich mit CDMO-Kunden ₹ 15 Crs. 9MGJ26 – Enthält außerordentliche Posten des Q3GJ26, die teilweise durch einmalige Insolvenzerlöse ausgeglichen werden, die im Q1GJ26 aus einer Klage gegen einen Drittlieferanten von CHG in Höhe von ₹ 21Crs. stammen. Telefonkonferenz
More news about: Piramal Pharma Limited
Jan 29, 2026, 15:35 ET SOLID FINISH TO 2025: MLG CAPITAL COMPLETES YEAR‑END ACQUISITIONS ACROSS TWO FUNDS
FINRA/SIPC. Its Form CRS may be found
More news about: MLG Capital
Jan 29, 2026, 13:24 ET Piramal Pharma Limited anuncia resultados del tercer trimestre y nueve meses del año fiscal 2026
la Ley LWF ₹ 26 Crs. y liquidación con clientes de CDMO ₹ 15 Crs.9MFY26 – Incluye partidas excepcionales del T3FY26 parcialmente compensadas por ingresos únicos por insolvencia recibidos en el T1FY26 de un reclamo presentado contra un proveedor externo de CHG por ₹ 21Crs. Conferencia
More news about: Piramal Pharma Limited
Jan 29, 2026, 13:17 ET Piramal Pharma Limited annonce ses résultats pour le troisième trimestre et les neuf premiers mois de l'exercice 2026
1. T3EX2026 - Inclut les provisions pour gratifications et congés payés en raison de l'impact de la modification de la loi LWF ₹ 26 Crs. et le règlement avec les clients CDMO ₹ 15 Cr. 9MEX2026 - Inclut les éléments exceptionnels du T3EX2026 partiellement compensés par
More news about: Piramal Pharma Limited
Jan 29, 2026, 00:46 ET Piramal Pharma Limited Announces Results for Q3 and 9M FY26
Act ₹ 26 Crs. & Settlement with CDMO customers ₹ 15 Crs. 9MFY26 – Includes exceptional items of Q3FY26 partially offset by one time insolvency proceeds received in Q1FY26 from a claim filed against a third-party supplier of CHG by ₹ 21Crs.
More news about: Piramal Pharma Limited
Jan 29, 2026, 00:35 ET Piramal Pharma Limited Announces Results for Q3 and 9M FY26
Act ₹ 26 Crs. & Settlement with CDMO customers ₹ 15 Crs. 9MFY26 – Includes exceptional items of Q3FY26 partially offset by one time insolvency proceeds received in Q1FY26 from a claim filed against a third-party supplier of CHG by ₹ 21Crs.
More news about: Piramal Pharma Limited
Jan 28, 2026, 08:30 ET Dominari Holdings Issues Letter to Shareholders
all of the principal invested. You can check the background of Dominari Securities and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at
More news about: Dominari Holdings Inc.
Jan 26, 2026, 19:00 ET Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma
next generation sequencing, with a threshold of 10-5, performed at a central laboratory.All cases of cytokine release syndrome (CRS) were Grade 1-2, with only 2 cases of Grade 1-2 immune effector cell-associated neurotoxicity syndrome (ICANS) reported. Most treatment-emergent adverse
More news about: Innovent Biologics
Jan 26, 2026, 10:16 ET Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets
at month 6, while DL2 decreased 65% at month 3 and 78% at month 6. Clinical SLEDAI-2K of 0 was achieved in 5 out of 10 patients with no Grade >2 CRS, ICANS, or GVHD reported.Ardelyx (NASDAQ: ARDX)
More news about: Equity Insider
Jan 16, 2026, 13:43 ET AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
serious side effects, including:Cytokine release syndrome (CRS), which is common during treatment with EPKINLY and can be serious or lead to death. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 2 or 3 smaller
More news about: AbbVie
Jan 15, 2026, 20:00 ET Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs
for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune diseases, solid tumors and hematological
More news about: Antengene Corporation Limited
Jan 15, 2026, 06:00 ET Cowbell Appoints Simon Hughes as Chief Commercial Officer
in commercial and specialty lines, including cyber, technology errors and omissions, and management liability. Through Cowbell Resiliency Services (CRS)—an independent cybersecurity advisory arm—policyholders gain access to Digital Forensics and Incident Response (DFIR) services as well as proactive solutions
More news about: Cowbell Cyber, Inc.
Jan 14, 2026, 16:30 ET TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide
release syndrome (CRS), including life-threatening or fatal reactions. In the clinical trial, CRS occurred in 72% of patients who received TECVAYLI® at the recommended dose, with Grade 1 CRS occurring in 50% of patients, Grade 2 in 21%, and Grade 3 in 0.6%. Recurrent CRS occurred in 33% of
More news about: Johnson & Johnson
Jan 14, 2026, 10:00 ET McWhinney Rebrands as Realberry, Advancing a More Accessible Real Estate Investment Platform
any particular security, strategy, or investment.Securities offered through North Capital Private Securities, Member FINRA/SIPC. Its Form CRS may be found
More news about: Realberry